908 Devices posts 23% Q2 revenue growth, lifts 2026 outlook
908 Devices Inc. reported strong growth for the quarter ended June 30, 2026, with revenue of $16.1 million, up 23% year-over-year, driven by VipIR product demand and initial NIRLab contribution.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
908 Devices Inc. reported strong growth for the quarter ended June 30, 2026, with revenue of $16.1 million, up 23% year-over-year, driven by VipIR product demand and initial NIRLab contribution. The installed base grew 23% to 4,101 devices, including 198 devices placed in the quarter, and recurring revenue represented 31% of total revenue.
GAAP gross profit was $8.3 million with a 52% gross margin, while adjusted gross margin improved to 57%. Operating expenses were $21.2 million, including a sizeable noncash charge from the change in fair value of contingent consideration, leading to a net loss from continuing operations of $11.9 million. Adjusted EBITDA loss narrowed to $1.9 million, more than half the prior-year level.
The company held $101.5 million in cash, cash equivalents and marketable securities as of June 30, 2026, with no debt, after using $13.5 million for the NIRLAB SA acquisition and receiving $3.5 million from an escrow release. Full-year 2026 revenue guidance was raised at the low end to $68.0–$70.0 million, representing 21%–25% growth versus 2025.
Positive
- Revenue grew 23% year-over-year in Q2 2026 to $16.1 million, reflecting strong product demand, particularly for VipIR and contributions from NIRLab.
- Full-year 2026 revenue guidance increased to $68.0–$70.0 million, implying 21%–25% growth versus 2025.
- Adjusted EBITDA loss improved significantly to -$1.9 million from -$3.9 million, with management highlighting a reduction of more than half versus a year ago.
- Cash, cash equivalents and marketable securities totaled $101.5 million with no debt, providing a solid liquidity position after funding the NIRLAB SA acquisition.
Negative
- Net loss from continuing operations remained sizable at -$11.9 million in Q2 2026, reflecting high operating expenses and large noncash contingent consideration charges.
- Total stockholders’ equity declined to $126.8 million from $143.7 million at December 31, 2025, driven by continued losses and acquisition-related impacts.
Insights
Analyzing...
8-K Event Classification
Key Figures
Key Terms
Adjusted EBITDA financial
recurring revenue financial
contingent consideration financial
discontinued operations financial
non-GAAP financial measures financial
Earnings Snapshot
Management expects full-year 2026 revenue of $68.0–$70.0 million, representing 21%–25% year-over-year growth, and raised the low end of its prior revenue outlook.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did 908 Devices (MASS) perform financially in Q2 2026?
What 2026 revenue guidance did 908 Devices (MASS) provide?
What is 908 Devices’ (MASS) cash position as of June 30, 2026?
How are margins and profitability trending for 908 Devices (MASS)?
What drove revenue growth for 908 Devices (MASS) in Q2 2026?
How large is 908 Devices’ (MASS) installed base and recurring revenue mix?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
| | |||
(State or other jurisdiction | (Commission | (I.R.S. Employer |
(Address of principal executive offices, including zip code)
(
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 11, 2026, 908 Devices Inc. (“908 Devices”) announced its preliminary financial results for the second quarter and fiscal year ended December 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.
The information contained in Item 2.02 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No. | | Description |
|
| |
99.1 | Press release issued by 908 Devices on August 11, 2026 | |
104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 11, 2026 | 908 Devices Inc. | |
|
| |
| By: | /s/ Mark S. Levine |
| Name: Mark S. Levine | |
| Title: Chief Legal and Administrative Officer | |
Exhibit 99.1
908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
Revenue increased 23% compared to prior year
Updated full year 2026 outlook reflects 21% to 25% year-over-year growth
BURLINGTON, Mass. – August 11, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended June 30, 2026.
“We delivered another strong quarter, growing revenue 23% year-over-year, while narrowing our Adjusted EBITDA loss by more than half compared to a year ago,” said Kevin J. Knopp, CEO and Co-founder. “Our momentum with U.S. state and local customers remained particularly strong, representing more than half of our revenue, as agencies modernize to address today's threats and hazards. Our newest FTIR product, VipIR, is leading that charge, and we surpassed our 100th unit shipped since launch. With the same commercial channel behind that momentum, we are now introducing NIRLab to the U.S. market. In just our first 60 days since deal close, we have engaged hundreds of prospects nationwide across more than 30 agencies. With a robust pipeline of opportunities, we are confident in our team's ability to deliver, and we remain committed to the disciplined execution of our strategy.”
Recent Highlights
| ● | Revenue of $16.1 million for the second quarter of 2026, increasing 23% year-over-year |
| ● | Recurring revenue was $4.9 million, representing 31% of total revenues for the quarter |
| ● | Gross margin was 52% and adjusted gross margin was 57% for the second quarter of 2026, an 85-basis point improvement in adjusted gross margin compared to the second quarter of 2025 |
| ● | Net loss from continuing operations was $11.9 million and Adjusted EBITDA loss was $1.9 million for the second quarter of 2026, a reduction of more than 50% year-over-year |
| ● | Ended the quarter with a strong balance sheet, with a cash position of $101.5 million |
| ● | Shipped more than 35 VipIR chemical identification devices in the quarter, including 18 units to a major South Asia law enforcement agency |
| ● | Subsequent to quarter end, secured a $6 million ProtectIR order from a corrections agency in the Asia-Pacific region, further supporting our second-half revenue outlook |
Second Quarter 2026 Financial Results
Revenue was $16.1 million for the three months ended June 30, 2026, a 23% increase over the prior year period, driven by an increase in product revenue for VipIR and the addition of NIRLab revenue. The installed base grew 23% year-over-year to 4,101 devices, with 198 devices placed during the second quarter. Recurring revenue represented 31% of total revenues in the quarter.
Gross profit was $8.3 million for the second quarter of 2026, compared to $6.4 million for the corresponding period in the prior year. GAAP gross margin was 52% as compared to 49% for the corresponding prior year period. Adjusted gross profit was $9.2 million for the second quarter of 2026, compared to $7.3 million for the corresponding period in the prior year. Adjusted gross margin was 57%, as compared to 56% for the corresponding prior year period. The increase in adjusted gross margin percentage was primarily driven by higher product revenues, including a shift in channel mix.
Operating expenses were $21.2 million for the second quarter of 2026, compared to $21.5 million for the corresponding prior year period. The decrease of $0.3 million includes a noncash decrease of $0.3 million related to a change in the fair value of the contingent consideration liability.
Net loss from continuing operations was $11.9 million for the second quarter of 2026, compared to a net loss from continuing operations of $12.9 million for the corresponding prior year period. Adjusted EBITDA was a loss of $1.9 million for the second quarter of 2026, compared to a loss of $3.9 million for the corresponding period in the prior year.
Net loss attributable to common stockholders was $11.9 million for the second quarter of 2026, compared to $13.3 million for the corresponding prior year period.
Cash, cash equivalents and marketable securities were $101.5 million as of June 30, 2026, with no debt outstanding. In the second quarter of 2026, $13.5 million of cash and cash equivalents were used for the acquisition of NIRLAB SA and $3.5 million was received from the release of the escrow from the desktop divestiture.
2026 Guidance
908 Devices updates its full year revenue guidance range to $68.0 million to $70.0 million (from $67.0 million to $70.0 million previously), raising the low end of the range and representing 21% to 25% growth compared to 2025 revenue.
Webcast Information
908 Devices will host a conference call to discuss the second quarter 2026 financial results before market open on Tuesday, August 11, 2026 at 8:30 am Eastern Time. A webcast of the conference call can be accessed in the Investor Relations section of 908devices.com. The webcast will be archived and available for replay for at least 90 days after the event.
About 908 Devices
908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com.
Non-GAAP Measures of Financial Performance
To supplement the Company’s financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release and presented with detailed reconciliations to comparable GAAP financial results in the tables below:
| ● | Adjusted gross profit is defined as gross profit excluding intangible amortization, acquisition and integration costs, restructuring charges (including the costs of severance), and non-cash expenses related to stock-based compensation. |
| ● | Adjusted gross margin is defined as adjusted gross profit expressed as a percentage of total revenue. |
| ● | Adjusted EBITDA is defined as net income (loss) from continuing operations excluding other income, benefit for income taxes, depreciation, intangible amortization, acquisition and integration costs, restructuring charges (including the costs of severance), non-cash expenses related to stock-based compensation, and costs associated with contingent consideration related to the Company’s acquisitions and for which the conditions for payment have not yet been achieved. |
The Company’s non-GAAP financial results presented in this earnings release exclude certain costs that management believes do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of ongoing operations for the period in which such charges are recorded, nor do the resulting charges recorded accurately reflect the anticipated cash flows of ongoing operations, and as such, excluding these costs allows management to understand and evaluate core operating performance and trends. However, as there are no standardized methods of calculating these non-GAAP financial measures, the Company’s methods may differ from those used by other companies in its industry, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness for purposes of comparison. Furthermore, these non-GAAP measures have certain limitations since they do not include the impact of certain expenses and cash flows that are reflected in the Company’s GAAP financial results. Accordingly, when analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures in isolation or as a substitute for, or superior to, comparable financial measures prepared in accordance with GAAP. Rather, the Company believes that these non-GAAP financial measures, when viewed in addition to and not in lieu of reported GAAP financial results, provide investors with additional meaningful information to assess financial performance and trends, enable comparison of financial results between periods, and allow for greater transparency with respect to key metrics utilized internally in analyzing and operating the Company’s business.
Forward Looking Statements
This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth and future business prospects and market opportunities. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are
based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission (SEC) which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
Investor and Media Contact:
Barbara Russo
IR@908devices.com
908 DEVICES INC.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(unaudited)
| | Three Months Ended June 30, | | Six Months Ended June 30, | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
Revenue: | | | | | | | | | | | | |
Product revenue | | $ | 12,974 | | $ | 9,577 | | $ | 23,711 | | $ | 18,106 |
Service and contract revenue | | | 3,100 | | | 3,458 | | | 5,745 | | | 6,707 |
Total revenue | |
| 16,074 | |
| 13,035 | |
| 29,456 | |
| 24,813 |
Cost of revenue: | |
| | |
| | |
| | |
| |
Product cost of revenue | |
| 6,412 | |
| 5,323 | |
| 11,573 | |
| 10,048 |
Service and contract cost of revenue | | | 1,319 | | | 1,339 | | | 2,658 | | | 2,850 |
Total cost of revenue | |
| 7,731 | |
| 6,662 | |
| 14,231 | |
| 12,898 |
Gross profit | |
| 8,343 | |
| 6,373 | |
| 15,225 | |
| 11,915 |
Operating expenses: | |
| | |
| | |
| | |
| |
Research and development | |
| 3,598 | |
| 4,405 | |
| 7,069 | |
| 8,234 |
Selling, general and administrative | |
| 11,112 | |
| 10,337 | |
| 21,027 | |
| 20,576 |
Change in fair value of contingent consideration | |
| 6,442 | |
| 6,792 | |
| 12,823 | |
| 9,291 |
Total operating expenses | |
| 21,152 | |
| 21,534 | |
| 40,919 | |
| 38,101 |
Loss from operations | | | (12,809) | | | (15,161) | | | (25,694) | | | (26,186) |
Other income, net | | | 861 | | | 2,324 | | | 1,791 | | | 3,512 |
Loss from continuing operations before income taxes | | | (11,948) | | | (12,837) | | | (23,903) | | | (22,674) |
Income tax benefit (expense), net | | | 54 | | | (71) | | | 54 | | | (71) |
Net loss from continuing operations | | | (11,894) | | | (12,908) | | | (23,849) | | | (22,745) |
Net income (loss) from discontinued operations, net of tax | |
| — | |
| (398) | |
| — | |
| 53,042 |
Net income (loss) attributable to common stockholders | | $ | (11,894) | | $ | (13,306) | | $ | (23,849) | | $ | 30,297 |
Net income (loss) from continuing operations per share attributable to common stockholders, basic and diluted | | $ | (0.32) | | $ | (0.36) | | $ | (0.64) | | $ | (0.64) |
Net income (loss) from discontinued operations per share attributable to common stockholders, basic and diluted | | $ | — | | $ | (0.01) | | $ | — | | $ | 1.49 |
Net income (loss) per share attributable to common stockholders, basic and diluted | | $ | (0.32) | | $ | (0.37) | | $ | (0.64) | | $ | 0.85 |
Weighted average common shares outstanding | | | | | | | | | | | | |
Basic and diluted | | | 37,727,668 | | | 35,877,947 | | | 37,275,671 | | | 35,633,573 |
908 DEVICES INC.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
| | June 30, | | December 31, | ||
| | 2026 | | 2025 | ||
Assets |
| | |
| | |
Current assets: |
| | |
| | |
Cash, cash equivalents and marketable securities | | $ | 101,531 | | $ | 112,970 |
Accounts receivable, net | |
| 11,710 | |
| 11,327 |
Inventory | |
| 14,372 | |
| 12,990 |
Prepaid expenses and other current assets | | | 4,407 | |
| 7,272 |
Total current assets | |
| 132,020 | |
| 144,559 |
Operating lease, right-of-use assets | |
| 4,009 | |
| 4,397 |
Property and equipment, net | |
| 4,605 | |
| 4,232 |
Goodwill | | | 11,055 | | | — |
Intangible, net | | | 45,115 | | | 36,412 |
Other long-term assets | |
| 734 | |
| 471 |
Total assets | | $ | 197,538 | | $ | 190,071 |
Liabilities and Stockholders' Equity | |
| | |
| |
Current liabilities: | |
| | |
| |
Accounts payable and accrued expenses | | $ | 8,472 | | $ | 8,424 |
Deferred revenue | |
| 10,711 | |
| 8,934 |
Operating lease liabilities and other liabilities | | | 30,239 | |
| 16,706 |
Total current liabilities | |
| 49,422 | |
| 34,064 |
Deferred revenue, net of current portion | |
| 11,012 | |
| 8,331 |
Contingent consideration, net of current portion | | | 5,860 | | | — |
Other long-term liabilities | | | 4,478 | | | 3,977 |
Total liabilities | |
| 70,772 | |
| 46,372 |
Total stockholders' equity | |
| 126,766 | |
| 143,699 |
Total liabilities and stockholders' equity | | $ | 197,538 | | $ | 190,071 |
908 DEVICES INC.
Reconciliations of GAAP to Non-GAAP Financial Measures
(Unaudited, amounts in thousands, except percentage and per share data)
In all tables below, totals may not add due to rounding
Reconciliation from Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP) and Margin Percentage:
| | Three Months Ended | | Six Months Ended | ||||||||
| | June 30, | | June 30, | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
| | | | | | | | | | | | |
Gross Profit (GAAP) | | $ | 8,343 | | | 6,373 | | | 15,225 | | | 11,915 |
| | | | | | | | | | | | |
Intangible amortization | | | 734 | | | 634 | | | 1,369 | | | 1,269 |
Acquisition and integration costs | | | - | | | - | | | - | | | 50 |
Restructuring | | | - | | | 222 | | | - | | | 288 |
Stock-based compensation | | | 107 | | | 107 | | | 262 | | | 223 |
| | | | | | | | | | | | |
Adjusted Gross Profit (Non-GAAP) | | $ | 9,184 | | $ | 7,336 | | $ | 16,856 | | $ | 13,745 |
| | | | | | | | | | | | |
Gross Margin Percentage (GAAP) | | | 52% | | | 49% | | | 52% | | | 48% |
| | | | | | | | | | | | |
Adjusted Gross Margin Percentage (Non-GAAP) | | | 57% | | | 56% | | | 57% | | | 55% |
| | | | | | | | | | | | |
Reconciliation from Net Income (Loss) from Continuing Operations (GAAP) to Adjusted EBITDA (Non-GAAP):
| | Three Months Ended | | Six Months Ended | ||||||||
| | June 30, | | June 30, | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
| | | | | | | | | | | | |
Net Loss from continuing operation (GAAP) | | $ | (11,894) | | | (12,908) | | | (23,849) | | | (22,745) |
| | | | | | | | | | | | |
Adjustments: | | | | | | | | | | | | |
Other income, net | | | (861) | | | (2,324) | | | (1,791) | | | (3,512) |
Benefit (Provision) for income taxes | | | (54) | | | 71 | | | (54) | | | 71 |
Depreciation | | | 442 | | | 260 | | | 848 | | | 551 |
Intangible amortization | | | 928 | | | 713 | | | 1,661 | | | 1,426 |
Acquisition and integration costs | | | 696 | | | - | | | 1,134 | | | 640 |
Restructuring | | | - | | | 1,173 | | | - | | | 1,266 |
Stock-based compensation | | | 2,313 | | | 2,337 | | | 4,712 | | | 4,557 |
Change in fair value of NIRLAB holdback shares | | | 64 | | | - | | | 64 | | | - |
Change in fair value of contingent consideration | | | 6,442 | | | 6,792 | | | 12,823 | | | 9,291 |
| | | | | | | | | | | | |
Adjusted EBITDA (Non-GAAP) | | $ | (1,924) | | $ | (3,886) | | $ | (4,452) | | $ | (8,455) |